WEKO3
-
RootNode
アイテム
Low immunogenicity of vedolizumab determined by a simple drug-tolerant assay in patients with ulcerative colitis.
http://hdl.handle.net/10422/00013202
http://hdl.handle.net/10422/000132026a657c40-d299-47e5-b76f-52ff64b69605
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
jcbn.21-98 (453.0 kB)
|
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License.
https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2022-02-02 | |||||
| タイトル | ||||||
| タイトル | Low immunogenicity of vedolizumab determined by a simple drug-tolerant assay in patients with ulcerative colitis. | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | vedolizumab | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | anti-vedolizumab antibody | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | therapeutic drug monitoring | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | open access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
| 著者 |
YAMASHITA, Noriaki
× YAMASHITA, Noriaki× IMAI, Takayuki× KAWAHARA, Masahiro× INATOMI, Osamu× ANDOH, Akira |
|||||
| 著者別名 |
山下, 典亮
× 山下, 典亮× 今井, 隆行× 河原, 真大× 稲富, 理× 安藤, 朗 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Vedolizumab is a humanized monoclonal antibody against the α4β7 integrin and is approved for treatment of inflammatory bowel diseases. In this study, we evaluated the immunogenicity of vedolizumab using a simple drug-tolerant assay developed in our laboratory. Serum vedolizumab trough levels and anti-vedolizumab antibody (AVA) levels were measured using new immunoassays in 37 patients with ulcerative colitis (UC) under vedolizumab maintenance therapy. The median vedolizumab trough level at week 30 was 16.0 μg/ml (interquartile range, 7.3-24.4). The vedolizumab trough level of the patients with clinical remission (partial Mayo score ≤1) was significantly higher than that of clinically active patients (16.7 μg/ml vs 6.8). The cut-off value of vedolizumab level predicting clinical remission at week 30 was 7.34 μg/ml. The median AVA level of patients under vedolizumab maintenance therapy was similar to that of healthy controls (n = 20) (0.032 μg/ml-c vs 0.022). One of 37 patients (2.7%) was judged to be AVA positive. There was no significant difference in serum AVA and vedolizumab trough levels between biologics-naïve (n = 19) and biologics-switched (prior anti-TNFα-exposed) patients (n = 18). In conclusion, the simple drug-tolerant assay developed in our laboratory demonstrated low immuno-genicity of vedolizumab. Prior use of anti-TNFα drugs did not affect the immunogenicity of vedolizumab. | |||||
| 言語 | en | |||||
| 書誌情報 |
en : Journal of Clinical Biochemistry and Nutrition 巻 70, 号 1, p. 72-78, 発行日 2022-01 |
|||||
| 出版者 | ||||||
| 出版者 | The Society for Free Radical Research Japan | |||||
| 言語 | en | |||||
| ISSN | ||||||
| 収録物識別子タイプ | PISSN | |||||
| 収録物識別子 | 0912-0009 | |||||
| PMID | ||||||
| 識別子タイプ | PMID | |||||
| 関連識別子 | 35068684 | |||||
| PMCID | ||||||
| 関連タイプ | isIdenticalTo | |||||
| 識別子タイプ | URI | |||||
| 関連識別子 | http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8764101/ | |||||
| 関連名称 | PMC8764101 | |||||
| DOI | ||||||
| 関連タイプ | isIdenticalTo | |||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | https://doi.org/10.3164/jcbn.21-98 | |||||
| 権利 | ||||||
| 言語 | en | |||||
| 権利情報 | © 2022 JCBN | |||||
| 著者版フラグ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
